New prognostic markers in neuroblastoma

Bibliography

• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3(3):203-16
   PubMed Web of Science ®Google Scholar
• Spix C, Pastore G, Sankila R, Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081-91
   PubMed Web of Science ®Google Scholar
• van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene 2004;325:1-15
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD, London WB, The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27(2):289-97
   PubMed Web of Science ®Google Scholar
• Ora I, Eggert A. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol 2011;21(4):217-28
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Pritchard J, Berthold F, Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11(8):1466-77
   PubMed Web of Science ®Google Scholar
• Monclair T, Brodeur GM, Ambros PF, The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27(2):298-303
   PubMed Web of Science ®Google Scholar
• Evans AE. Staging and treatment of neuroblastoma. Cancer 1980;45(7 Suppl):1799-802
   PubMed Web of Science ®Google Scholar
• Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31(12):2098-103
   PubMed Web of Science ®Google Scholar
• London WB, Castleberry RP, Matthay KK, Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23(27):6459-65
   PubMed Web of Science ®Google Scholar
• Miettinen M, Chatten J, Paetau A, Stevenson A. Monoclonal antibody NB84 in the differential diagnosis of neuroblastoma and other small round cell tumors. Am J Surg Pathol 1998;22(3):327-32
   PubMed Web of Science ®Google Scholar
• Shimada H, Umehara S, Monobe Y, International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92(9):2451-61
   PubMed Web of Science ®Google Scholar
• PeuchmaurM, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98(10):2274-81
   PubMed Web of Science ®Google Scholar
• Burgues O, Navarro S, Noguera R, Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch 2006;449(4):410-20
   PubMed Web of Science ®Google Scholar
• Navarro S, Amann G, Beiske K, Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. J Clin Oncol 2006;24(4):695-9
   PubMed Web of Science ®Google Scholar
• Ambros PF, Ambros IM, Brodeur GM, International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009;100(9):1471-82
   PubMed Web of Science ®Google Scholar
• Piqueras M, Navarro S, Canete A, Prognostic value of partial genetic instability in neuroblastoma with </= 50% neuroblastic cell content. Histopathology 2011;59(1):22-30
   PubMed Web of Science ®Google Scholar
• Kryh H, Caren H, Erichsen J, Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics 2011;12:443
   PubMedGoogle Scholar
• Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010;28(19):3122-30
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Schleiermacher G, Michels E, Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27(7):1026-33
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Seeger RC, Schwab M, Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224(4653):1121-4
   PubMed Web of Science ®Google Scholar
• Seeger RC, Brodeur GM, Sather H, Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313(18):1111-16
   PubMed Web of Science ®Google Scholar
• Attiyeh EF, London WB, Mosse YP, Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353(21):2243-53
   PubMed Web of Science ®Google Scholar
• Caren H, Kryh H, Nethander M, High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 2010;107(9):4323-8
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369(9579):2106-20
   PubMed Web of Science ®Google Scholar
• Henrich KO, Bauer T, Schulte J, CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res 2011;71(8):3142-51
   PubMed Web of Science ®Google Scholar
• George RE, London WB, Cohn SL, Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23(27):6466-73
   PubMed Web of Science ®Google Scholar
• Schneiderman J, London WB, Brodeur GM, Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol 2008;26(6):913-18
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Knudson AG. Mechanism and relevance of ploidy in neuroblastoma. Genes Chromosomes Cancer 2000;29(2):89-95
   PubMed Web of Science ®Google Scholar
• Brisse HJ, McCarville MB, Granata C, Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261(1):243-57
   PubMed Web of Science ®Google Scholar
• Naranjo A, Parisi MT, Shulkin BL, Comparison of (1)(2)(3)I-metaiodobenzylguanidine (MIBG) and (1)(3)(1)I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011;56(7):1041-5
   PubMed Web of Science ®Google Scholar
• Messina JA, Cheng SC, Franc BL, Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47(7):865-74
   PubMed Web of Science ®Google Scholar
• Piccardo A, Lopci E, Conte M, Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012;39(1):57-71
   PubMed Web of Science ®Google Scholar
• Swerts K, Ambros PF, Brouzes C, Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. J Histochem Cytochem 2005;53(12):1433-40
   PubMed Web of Science ®Google Scholar
• Kryh H, Abrahamsson J, Jegeras E, MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma. Int J Oncol 2011;39(5):1063-71
   PubMed Web of Science ®Google Scholar
• Burchill SA, Kinsey SE, Picton S, Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 2001;36(1):213-19
   PubMedGoogle Scholar
• Oltra S, Martinez F, Orellana C, The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol 2005;14(1):53-7
   PubMed Web of Science ®Google Scholar
• Viprey VF, Lastowska MA, Corrias MV, Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol 2008;216(2):245-52
   PubMed Web of Science ®Google Scholar
• Corrias MV, Parodi S, Haupt R, Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma. Br J Cancer 2008;98(2):263-9
   PubMed Web of Science ®Google Scholar
• Yanez Y, Grau E, Oltra S, Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. J Cancer Res Clin Oncol 2011;137(8):1263-72
   PubMed Web of Science ®Google Scholar
• Ambros IM, Hata J, Joshi VV, Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer 2002;94(5):1574-83
   PubMed Web of Science ®Google Scholar
• Tornoczky T, Semjen D, Shimada H, Ambros IM. Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma. Pathol Oncol Res 2007;13(4):269-75
   PubMed Web of Science ®Google Scholar
• Sano H, Gonzalez-Gomez I, Wu SQ, A case of composite neuroblastoma composed of histologically and biologically distinct clones. Pediatr Dev Pathol 2007;10(3):229-32
   PubMed Web of Science ®Google Scholar
• Amar P, Ballet P, Barlovatz-Meimon G, Hyperstructures, genome analysis and I-cells. Acta Biotheor 2002;50(4):357-73
   PubMed Web of Science ®Google Scholar
• Huang S, Ingber DE. A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. Breast Dis 2006;26:27-54
   PubMedGoogle Scholar
• Noguera R, Nieto OA, Tadeo I, Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histol Histopathol 2012;27(6):693-705
   PubMed Web of Science ®Google Scholar
• Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 2011;21(4):229-37
   PubMed Web of Science ®Google Scholar
• Pietras A, Hansford LM, Johnsson AS, HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA 2009;106(39):16805-10
   PubMed Web of Science ®Google Scholar
• Lam WA, Cao L, Umesh V, Extracellular matrix rigidity modulates neuroblastoma cell differentiation and N-myc expression. Mol Cancer 2010;9:35
   PubMedGoogle Scholar
• Villamon E, Piqueras M, Berbegall AP, Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumors. Histol Histopathol 2011;26(3):343-50
   PubMed Web of Science ®Google Scholar
• Vandesompele J, Michels E, De Preter K, Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. Int J Cancer 2008;122(5):1177-82
   PubMed Web of Science ®Google Scholar
• Combaret V, Bergeron C, Noguera R, Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol 2005;23(34):8919-20; author reply 20
   PubMed Web of Science ®Google Scholar
• Yagyu S, Iehara T, Gotoh T, Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Lett 2011;309(2):185-9
   PubMed Web of Science ®Google Scholar
• Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 1994;55(2):334-40
   PubMed Web of Science ®Google Scholar
• Van Roy N, Laureys G, Cheng NC, 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 1994;10(2):103-14
   PubMed Web of Science ®Google Scholar
• Bown N, Cotterill S, Lastowska M, Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340(25):1954-61
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Penther D, Thioux M, Molecular analysis of chromosome arm 17q gain in neuroblastoma. Genes Chromosomes Cancer 2000;28(3):276-84
   PubMed Web of Science ®Google Scholar
• Combaret V, Brejon S, Iacono I, Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer 2011;56(5):757-61
   PubMed Web of Science ®Google Scholar
• Ambros IM, Brunner B, Aigner G, A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 2011;17(4):792-804
   PubMed Web of Science ®Google Scholar
• Schleiermacher G, Michon J, Ribeiro A, Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer 2011;105(12):1940-8
   PubMed Web of Science ®Google Scholar
• Molenaar JJ, Koster J, Zwijnenburg DA, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483(7391):589-93
   PubMed Web of Science ®Google Scholar
• Maris JM, Mosse YP, Bradfield JP, Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008;358(24):2585-93
   PubMed Web of Science ®Google Scholar
• Capasso M, Devoto M, Hou C, Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009;41(6):718-23
   PubMed Web of Science ®Google Scholar
• Wang K, Diskin SJ, Zhang H, Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011;469(7329):216-20
   PubMed Web of Science ®Google Scholar
• Nguyen le B, Diskin SJ, Capasso M, Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet 2011;7(3):e1002026
   PubMedGoogle Scholar
• Diskin SJ, Hou C, Glessner JT, Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009;459(7249):987-91
   PubMed Web of Science ®Google Scholar
• Hiyama E, Hiyama K, Yokoyama T, Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn J Cancer Res 1992;83(2):159-64
   PubMedGoogle Scholar
• Ohali A, Avigad S, Ash S, Telomere length is a prognostic factor in neuroblastoma. Cancer 2006;107(6):1391-9
   PubMed Web of Science ®Google Scholar
• Lundberg G, Sehic D, Lansberg JK, Alternative lengthening of telomeres–an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer 2011;50(4):250-62
   PubMed Web of Science ®Google Scholar
• Cheung NK, Zhang J, Lu C, Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307(10):1062-71
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Lequin D, Brugieres L, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455(7215):967-70
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Longo L, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455(7215):930-5
   PubMed Web of Science ®Google Scholar
• Subramaniam MM, Piqueras M, Navarro S, Noguera R. Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas. Hum Pathol 2009;40(11):1638-42
   PubMed Web of Science ®Google Scholar
• McConville C, Reid S, Baskcomb L, PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. Am J Med Genet A 2006;140(12):1297-301
   PubMedGoogle Scholar
• Reiff T, Tsarovina K, Majdazari A, Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons. J Neurosci 2010;30(3):905-15
   PubMed Web of Science ®Google Scholar
• Bachetti T, Di Paolo D, Di Lascio S, PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS One 2010;5(10):e13108
   PubMedGoogle Scholar
• Berthier A, Piqueras M, Villamon E, Anaplastic lymphoma kinase expression in neuroblastomas and its relationship with genetic, prognostic, and predictive factors. Hum Pathol 2011;42(2):301-2
   PubMed Web of Science ®Google Scholar
• Schulte JH, Horn S, Schlierf S, MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett 2009;274(1):10-15
   PubMed Web of Science ®Google Scholar
• Gomez-Mateo Mdel C, Piqueras M, Pahlman S, Prognostic value of SOX2 expression in neuroblastoma. Genes Chromosomes Cancer 2011;50(5):374-7
   PubMed Web of Science ®Google Scholar
• Sartelet H, Imbriglio T, Nyalendo C, CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 2012;60(7):1144-55
   PubMed Web of Science ®Google Scholar
• Lamers F, Schild L, Koster J, Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 2012;48(5):763-71
   PubMed Web of Science ®Google Scholar
• Bowen KA, Chung DH. Recent advances in neuroblastoma. Curr Opin Pediatr 2009;21(3):350-6
   PubMed Web of Science ®Google Scholar
• Lammens T, Swerts K, Derycke L, N-cadherin in neuroblastoma disease: expression and clinical significance. PLoS One 2012;7(2):e31206
   PubMedGoogle Scholar
• Holzel M, Huang S, Koster J, NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010;142(2):218-29
   PubMed Web of Science ®Google Scholar
• Huang S, Laoukili J, Epping MT, ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009;15(4):328-40
   PubMed Web of Science ®Google Scholar
• Oberthuer A, Berthold F, Warnat P, Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24(31):5070-8
   PubMed Web of Science ®Google Scholar
• Fardin P, Barla A, Mosci S, A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer 2010;9:185
   PubMedGoogle Scholar
• Gowda M, Godder K, Kmieciak M, Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med 2011;9:170
   PubMed Web of Science ®Google Scholar
• Oberthuer A, Hero B, Berthold F, Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28(21):3506-15
   PubMed Web of Science ®Google Scholar
• Vermeulen J, De Preter K, Naranjo A, Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10(7):663-71
   PubMed Web of Science ®Google Scholar
• De Preter K, Vermeulen J, Brors B, Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16(5):1532-41
   PubMed Web of Science ®Google Scholar
• Abel F, Dalevi D, Nethander M, A 6-gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell Int 2011;11:9
   PubMed Web of Science ®Google Scholar
• De Preter K, De Brouwer S, Van Maerken T, Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin Cancer Res 2009;15(11):3690-6
   PubMed Web of Science ®Google Scholar
• Wei JS, Johansson P, Chen QR, MicroRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009;15(17):5560-8
   PubMed Web of Science ®Google Scholar
• Guo J, Dong Q, Fang Z, Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol Ther 2010;9(6):446-52
   PubMedGoogle Scholar
• Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des 2009;15(4):456-62
   PubMed Web of Science ®Google Scholar
• Schulte JH, Schowe B, Mestdagh P, Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010;127(10):2374-85
   PubMed Web of Science ®Google Scholar
• Lin RJ, Lin YC, Chen J, MicroRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 2010;70(20):7841-50
   PubMed Web of Science ®Google Scholar
• Buckley PG, Alcock L, Bryan K, Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 2010;16(11):2971-8
   PubMed Web of Science ®Google Scholar
• De Preter K, Mestdagh P, Vermeulen J, MiRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011;17(24):7684-92
   PubMed Web of Science ®Google Scholar
• Alaminos M, Davalos V, Cheung NK, Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004;96(16):1208-19
   PubMed Web of Science ®Google Scholar
• Abe M, Watanabe N, McDonell N, Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 2008;74(1-2):50-60
   PubMed Web of Science ®Google Scholar
• Grau E, Martinez F, Orellana C, Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 2011;50(3):153-62
   PubMed Web of Science ®Google Scholar
• Michalowski MB, de Fraipont F, Plantaz D, Methylation of tumor-suppressor genes in neuroblastoma: the RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 2008;50(1):29-32
   PubMed Web of Science ®Google Scholar
• Yang Q, Kiernan CM, Tian Y, Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13(11):3191-7
   PubMed Web of Science ®Google Scholar
• Misawa A, Tanaka S, Yagyu S, RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer 2009;100(2):399-404
   PubMed Web of Science ®Google Scholar